MedTrace Logo

Sufentanil Pharmacokinetics After Intra Amniotic Injection

NCT02962830 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-12-03

No results posted yet for this study

Summary

The fetus may be exposed during pregnancy to nociceptive stimuli because of fetal pathology (e.g., malformation) or a diagnostic or therapeutic procedure.

To date, there is very little data and no consensus on fetal analgesia. The aim of the investigators study is to evaluate the pharmacokinetics of Sufentanil after intra amniotic injection.

Conditions

  • Prenatal Diagnosis

Interventions

DRUG

Sufentanil

intra-amniotic injection of 10 micrograms of Sufentanil

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Véronique HOUFFLIN-DEBARGE, MD, PhD · University Hospital, Lille

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-19
Primary Completion
2024-05-28
Completion
2024-05-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02962830 on ClinicalTrials.gov